$PFE (Pfizer Inc.) Support & Resistance Levels, AI Price Target & Institutional Flow.
Today, $PFE (Pfizer Inc.) trades at $27.45 (-0.51%) with a 85/100 Momentum Pulse (SUNNY) and 14D RSI at 21.4 (OVERSOLD VALUE (21.4)). Unlock the live $PFE support and resistance levels, 30D Put Wall floor, 20D SMA pivot, Call Wall ceiling, dark pool flow, and locked 1-Month AI Price Target (+14.2% upside corridor) below—or create a free 24/7 AI quant agent to guard $PFE.
Pfizer (PFE) stock is moving up today after reporting better-than-expected second-quarter 2026 earnings, raising its full-year revenue guidance midpoint due to strong non-COVID product sales, which offset declines in COVID-19 related products.
$PFE (Pfizer Inc.) Live Key Levels, RSI & Valuation Matrix
| $PFE Technical Metric | Live Value | $PFE Fundamental / Regime Metric | Live Status |
|---|---|---|---|
| Live Spot Price (24h Change) | $27.45 (-0.51%) | Market Capitalization | $156.17B |
| 30-Day Mechanical Support Floor (Put Wall) | $27.40 (0.18% cushion) | 52-Week High / Low Range | $23.62 – $31.44 |
| 20-Day Simple Moving Average (20D SMA) | $29.12 | Trailing P/E Ratio & Dividend Yield | 38.72x • Yield: 6.28% |
| 10-Day Exponential Moving Average (10D EMA) | $28.37 | Average Daily Volume (Liquidity) | 40.45M shares |
| 30-Day Resistance Ceiling (Call Wall) | $30.35 (10.55% upside to test) | Next Scheduled Earnings / Catalyst Window | 2026-11-03 |
| 14-Day Relative Strength Index (RSI) | OVERSOLD VALUE (21.4) | Saku Momentum Pulse & Health Rating | 85/100 Momentum • 70/100 Health |
Should You Buy $PFE Stock Now or Wait?
Pfizer's robust performance in its non-COVID product portfolio, enhanced revenue guidance, and ongoing productivity initiatives suggest a resilient business poised for sustained growth.
Declining COVID-19 product revenues and a notable pipeline setback in oncology highlight potential challenges in future growth and the need for successful new drug development.
$PFE Support & Resistance, Institutional Flow & Catalysts.
$PFE Support & Resistance
Spot Price: $27.45 | 30-Day Support Floor: $27.40 (0.18% above) | 10-Day EMA: $28.37 | 20-Day SMA Pivot: $29.12 | 30-Day Resistance Ceiling: $30.35 (10.55% below) | 14-Day RSI: 21.4 (OVERSOLD VALUE (21.4)) | 30-Day Trading Corridor: 10.75% span. AI Desk Note: Immediate support for PFE stock is at $24.80, with resistance at $25.33.
$PFE Institutional & Whale Flow
Increased institutional interest is likely as positive earnings and raised guidance typically attract large-scale investors.
$PFE Catalyst Outlook
Upcoming key pivotal readouts from its late-stage pipeline are expected over the next 12 months, with a PDUFA action date for Talzenna in Q4 2026.
Latest $PFE (Pfizer Inc.) Breaking News & Headlines
About Pfizer Inc. ($PFE)
Seagen and Astellas previously entered a clinical collaboration agreement with MSD to evaluate the combination of Seagen's and Astellas' PADCEV TM (enfortumab vedotin) and MSD's KEYTRUDA ® (pembrolizumab) in patients with urothelial cancer. Pfizer Inc. successfully completed its acquisition of Seagen on December 14, 2023. KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada). About XTANDI and the Pfizer/Astellas Collaboration In October 2009, Medivation, Inc., which is now part of Pfizer, and Astellas (TSE: 4503) entered into a commercial agreement to jointly develop and commercialize XTANDI ® (enzalutamide) in the United States, while Astellas has responsibility for manufacturing and all additional regulatory filings globally, as well as commercializing the product outside the United States.
Saku's quantitative engine continuously monitors $PFE's 30-day mechanical support floor ($27.40), 20-day simple moving average ($29.12), and 30-day resistance ceiling ($30.35) alongside off-exchange dark pool block prints and SEC filings.
Hatch Your Own 24/7 AI Co-Pilot to Guard $PFE.
Step inside the 3D Quant Sanctuary and claim Workstation #4 to hatch your personal AI analyst (Momentum, Dip-Buyer, or Value & Catalyst style). Your agent monitors $PFE 24/7 with locked 1-month price targets, hard stop-loss tripwires, 3x/day shift briefings, and live Koi Bridge debates.

What are the live 30-day support and resistance levels for $PFE (Pfizer Inc.)?
Spot Price: $27.45 | 30-Day Support Floor: $27.40 (0.18% above) | 10-Day EMA: $28.37 | 20-Day SMA Pivot: $29.12 | 30-Day Resistance Ceiling: $30.35 (10.55% below) | 14-Day RSI: 21.4 (OVERSOLD VALUE (21.4)) | 30-Day Trading Corridor: 10.75% span. AI Desk Note: Immediate support for PFE stock is at $24.80, with resistance at $25.33. $PFE currently registers a Saku Momentum Pulse score of 85/100 and a Fundamental Health score of 70/100.
Why is $PFE (Pfizer Inc.) moving and what is the bull vs. bear thesis?
Bull Thesis: Pfizer's robust performance in its non-COVID product portfolio, enhanced revenue guidance, and ongoing productivity initiatives suggest a resilient business poised for sustained growth. Bear Thesis: Declining COVID-19 product revenues and a notable pipeline setback in oncology highlight potential challenges in future growth and the need for successful new drug development.
What are $PFE's key fundamentals, 52-week range, and upcoming catalysts?
Pfizer Inc. ($PFE) trades with a market cap of $156.17B, a P/E ratio of 38.72x, and a 52-week range of $23.62 to $31.44. Upcoming key pivotal readouts from its late-stage pipeline are expected over the next 12 months, with a PDUFA action date for Talzenna in Q4 2026.